TELESIS BIO (TBIO)
(Real Time Quote from BATS)
$0.32 USD
0.00 (-0.41%)
Updated Apr 25, 2024 10:58 AM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Telesis Bio Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 28 | 27 | 11 | 7 | NA |
Cost Of Goods | 11 | 12 | 7 | 3 | NA |
Gross Profit | 17 | 16 | 4 | 4 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 63 | 62 | 40 | 20 | 0 |
Income After Depreciation & Amortization | -47 | -46 | -35 | -16 | 0 |
Non-Operating Income | 2 | -1 | -2 | -1 | NA |
Interest Expense | 3 | 1 | 1 | 1 | NA |
Pretax Income | -48 | -48 | -39 | -18 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -48 | -48 | -39 | -18 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -48 | -48 | -39 | -18 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -30 | -43 | -33 | -15 | 0 |
Depreciation & Amortization (Cash Flow) | 16 | 3 | 2 | 2 | NA |
Income After Depreciation & Amortization | -47 | -46 | -35 | -16 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 29.85 | 29.46 | 18.22 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.26 | -1.65 | -2.11 | NA | NA |
Diluted Net EPS (GAAP) | -1.64 | -1.65 | -2.14 | NA | NA |
Fiscal Year end for Telesis Bio Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 6.98 | 5.56 | 8.65 | 6.32 |
Cost Of Goods | NA | 2.23 | 2.57 | 2.96 | 2.81 |
Gross Profit | NA | 4.75 | 3.00 | 5.69 | 3.51 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 22.23 | 13.12 | 13.66 | 14.48 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -17.48 | -10.12 | -7.97 | -10.97 |
Non-Operating Income | NA | -0.11 | 0.19 | 0.02 | 0.10 |
Interest Expense | NA | 1.84 | 0.68 | 0.33 | 0.25 |
Pretax Income | NA | -17.68 | -10.62 | -8.28 | -11.12 |
Income Taxes | NA | 0.00 | 0.01 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -17.69 | -10.63 | -8.29 | -11.12 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -17.69 | -10.63 | -8.29 | -11.12 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 30.01 | 29.95 | 29.77 | 29.66 |
Diluted EPS Before Non-Recurring Items | NA | -0.23 | -0.37 | -0.28 | -0.37 |
Diluted Net EPS (GAAP) | NA | -0.62 | -0.37 | -0.28 | -0.37 |